Show simple item record

dc.contributor.authorClissold, RL
dc.contributor.authorAshfield, B
dc.contributor.authorBurrage, J
dc.contributor.authorHannon, E
dc.contributor.authorBingham, C
dc.contributor.authorMill, J
dc.contributor.authorHattersley, A
dc.contributor.authorDempster, EL
dc.date.accessioned2018-08-20T13:04:32Z
dc.date.issued2018-07-18
dc.description.abstractHeterozygous mutation of the transcription factor HNF1B is the most common cause of monogenetic developmental renal disease. Disease-associated mutations fall into two categories: HNF1B intragenic mutations and a 1.3 Mb deletion at chromosome 17q12. An increase in neurodevelopmental disorders has been observed in individuals harbouring the 17q12 deletion but not in patients with HNF1B coding mutations.Previous investigations have concentrated on identifying a genetic cause for the increase in behavioural problems seen in 17q12 deletion carriers. We have taken the alternative approach of investigating the DNA methylation profile of these two HNF1B genotype groups along with controls matched for age, gender and diabetes status using the Illumina 450K DNA methylation array (total sample n = 60).We identified a number of differentially methylated probes (DMPs) that were associated with HNF1B-associated disease and passed our stringent experiment-wide significance threshold. These associations were largely driven by the deletion patients and the majority of the significant probes mapped to the 17q12 deletion locus. The observed changes in DNA methylation at this locus were not randomly dispersed and occurred in clusters, suggesting a regulatory mechanism reacting to haploinsufficiency across the entire deleted region.Along with these deletion-specific changes in DNA methylation, we also identified a shared DNA methylation signature in both mutation and deletion patient groups indicating that haploinsufficiency of HNF1B impacts on the methylome of a number of genes, giving further insight to the role of HNF1B.en_GB
dc.description.sponsorshipRC is supported by a Medical Research Council Clinical Training Fellowship (grant reference number MR/J011630/1). AH is a core member of the NIHR Exeter Clinical Research Facility and a National Institute for Health Research Senior Investigator; he is also supported by a Wellcome Trust Senior Investigator award. ED is a recipient of an Academy of Medical Sciences Springboard Award.en_GB
dc.identifier.citationVol. 10: 97en_GB
dc.identifier.doi10.1186/s13148-018-0530-z
dc.identifier.urihttp://hdl.handle.net/10871/33791
dc.language.isoenen_GB
dc.publisherBioMed Centralen_GB
dc.relation.sourceThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.en_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/30021660en_GB
dc.rights© The Author(s). 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.en_GB
dc.subject17q12 deletionen_GB
dc.subjectAutismen_GB
dc.subjectCNVen_GB
dc.subjectDNA methylationen_GB
dc.subjectEpigeneticsen_GB
dc.subjectHNF1Ben_GB
dc.subjectRenal diseaseen_GB
dc.titleGenome-wide methylomic analysis in individuals with HNF1B intragenic mutation and 17q12 microdeletion.en_GB
dc.typeArticleen_GB
dc.date.available2018-08-20T13:04:32Z
exeter.place-of-publicationGermanyen_GB
dc.descriptionThis is the final version of the article. Available from the publisher via the DOI in this recorden_GB
dc.identifier.journalClinical Epigeneticsen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record